About Us

Committed to improving research and development productivity for organizations around the world through better science and technology.

BIOVIA Biologics Webinars

Many research organizations are increasing their efforts in biotherapeutic discovery and development. The research and development workflow for biologics is similar to that of small molecule at the highest level, but requires more unique processes inherent in the added complexity of biological systems. The BIOVIA Biologics Solution is designed to meet the needs of the individuals and teams who are a part of these processes.

The BIOVIA Biologics Solution is a suite of capabilities supported by a common platform. It is designed to help overcome barriers to innovation and process efficiency for the discovery and optimization of biotherapeutic candidates and the optimization of the overall workflow that includes development, manufacturing and compliance processes.

Webinars will continue to be added to this series, please check back often.

Past Webinars in the Series

Title and Speaker

Accurate Antibody Molecular Modeling Enables Epitope Determination
Guy Georges, Roche and Hugues-Olivier Bertrand, Dassault Systèmes BIOVIA

During the past few years, modeling tools for antibody discovery and engineering have been developed, taking advantage of the structural knowledge existing in the protein database (PDB).

At Roche, a modeling tool is automatically producing high quality models at a very low computational cost. The tool uses an antibody structural database dissected in heavy and light chains, frameworks, and Complement Determining Regions (CDRs) segments that enables novel features in searching templates during modeling. An accurate prediction of the relative VH-VL orientation ensures the model quality. The VH-VL orientation prediction is also used to predict the CDR grafting success during humanization.

Watch this webinar to learn how to automate the generation of high-quality antibody structure models.

 Watch Now

What to Make Next? Guiding Drug Design with In Silico Modeling
Dr. Adrian Stevens, Dassault Systèmes BIOVIA

In silico modeling tools offer a means for R&D teams to maximize the value of their research by augmenting physical experiments with model-based predictions.

Watch this webinar to discover:

  • What is BIOVIA’s predictive science strategy?
  • How we are going to combine in silico with the lab (V+R)?
  • What are the key steps for moving to a model-first paradigm?
 Watch Now

Rethinking Collaboration in Biologics Discovery
Dr. Anne Goupil, Principal Field Application Scientist, Dassault Systèmes BIOVIA

Today’s biotherapeutics research labs need to be able to successfully work with big data (genomics), public data, and various classes of experimental data to effectively operate in the modern world of biologics R&D. This environment only becomes more complex as many organisations are exploring external partnerships to leverage new sources of innovation. However, often not all of this data and associated meta-data is readily available to a project team as legacy systems and processes make sharing data across these collaborative networks prohibitively inefficient.

As a result, they are forced to make decisions without all of the information available to them, which can significantly hinder the quality and speed of biotherapeutic development.

Download this webinar to learn:

  • The increasingly complex networks and repositories of data available to biologics researchers
  • How to more successfully manage collaboration across internal and external research teams
  • Case Study: The value of the interaction of real time predictive models, genomics data, and assay data in biologics research
 Watch Now

Integrated, Predictive and Collaborative Workflows in Biologics Discovery

Many organisations have increased their efforts in biotherapeutic drug discovery. At GSK, biopharmaceutical assets have grown from <3% of GSK’s pipeline in 2008 to>25% in 2015. There are a number of drivers of this growth which include superior efficacy or satisfying a previously unmet clinical need. In biologics discovery scientists use many different software and analytical systems. Lack of integrated systems and data diversity creates many challenges. Management of this data on an integrated informatics platform will enable higher quality products, faster.

The design of an integrated workflow supported by a common platform can help with the discovery of biotherapeutic candidates, in particular with the management and analysis of scientific and quality data.

Join this webinar where BIOVIA and GSK will discuss the following:

  • Effective IP protection and decision making through secure collaboration
  • Highlight predictive analysis for candidate selection and capabilities to analyze, annotate and register biologic candidates in a framework that facilitates secure data sharing
  • Share the GSK experience with implementation of the Biological Registration solution.

 Watch Now

New Tools for Antibody Discovery
Neil Eccles, Sr. Product Manager

The discovery of promising antibodies for therapeutic use requires the molecular biologist to overcome many hurdles. In order to be successful, large volumes of sequence, property and activity data need to be digested and understood to enable the identification of the most promising candidates for further analysis and rational design. In this webinar, we will introduce you to a suite of tools from BIOVIA that help streamline this process and enable you to track the progress of antibody and antibody drug conjugate-based lead candidates through the discovery and development pipeline.

 Watch Now

Biologic Drugs: Manufacturing Better and Faster
Larry R. Fiegland, PH.D., Lead Field Application Scientist
Daniela Jansen, PH.D., Sr. Product Marketing Manager

In today's pharmaceutical manufacturing industry, there are major challenges with getting the data you need from all the disparate sources and paper records across the organization in order to make business decisions. Then when you get the data, it requires error-prone manual work to analyze and generate reports. Working in spreadsheets, dealing with the delay of getting the additional data needed and using un-validated analysis results and reports are all major problems that people face every day. This costs organizations time, resources and ultimately, money.

Join us for this live webinar and learn how The BIOVIA Biologics Manufacturing solution has already helped many top 100 pharma companies address the challenges noted above and learn what we can do for your business as well.

 Watch Now

Discovering Biologics Faster with BIOVIA Biotherapeutics Workbench
Tim Moran, Director, BIOVIA Life Sciences
Neil Eccles, Sr. Product Manager, Biologics

Early antibody discovery produces large volumes of antibody and assay activity data. There is a need for real-time project tracking and collaboration with various groups involved in the process, as well as a solution that is biologically aware and integrated with other laboratory systems from registration to process management.

The BIOVIA Biotherapeutics Workbench enables scientists to overcome barriers to innovation and process efficiency in antibody lead discovery, while saving time and reducing costs associated with errors or lack of accessible information early in the process. Built on the BIOVA foundation, the Biotherapeutics Workbench enables discovery teams to customize workflows to meet their specific needs. Researchers can replace manual error-prone processes of collecting, collating and analyzing data needed to make informed decisions about good antibody candidates for development.

In this webinar, you will learn how the BIOVIA Biotherapeutics Workbench can help you:

  • Rapidly import and annotate large numbers of antibody sequences
  • Visualize and analyze sequences and associated data
  • Cluster antibodies
  • Calculate developability properties
  • Define projects and export data


Tim Moran, Director, BIOVIA Life Sciences
Neil Eccles, Sr. Product Manager, Biologics

 Watch Now

Discovering Biologics Faster with BIOVIA Biological Registration (Bioreg)
Tim Moran, Director, BIOVIA Life Sciences
Neil Eccles, Sr. Product Manager, Biologics

BIOVIA Biological Registration enables you to register, search and report on a variety of biological entities from a simple, easy to use web client. Out-of-the-box, the system supports the registration of antibodies, hybridomas, immortalized cell lines, plasmids, proteins, siRNAs, yeasts and vaccines. Capabilities are also provided for developing chemically modified biological entities such as antibody drug conjugates or pegylated peptides for registration.

In this webinar, you will learn how BIOVIA Biological Registration enables you to:

  • Establish the identity of biological materials by determining their uniqueness and how they relate to one another so that you can avoid the confusion, errors and costs associated with mistakenly treating biological reagents as either identical or distinct and understand their lineage and origin
  • Track the progress of biological materials through development and discovery via corporate and lot identifiers assigned by the system
  • Meet current and future needs by creating new entities, modifying existing entities, or by modifying existing business rules for registration, all without having to write any code
  • Make better decisions faster by using real-time reports, dashboards and powerful query tools to give managers the information they need, exactly when they need it.
  • Reduce total cost of ownership by using an out-of-the-box system that offers flexibility, scalability, and reduced complexity to ensure that the total cost of ownership is lower than creating and maintaining an in-house solution.


Tim Moran, Director, BIOVIA Life Sciences
Neil Eccles, Sr. Product Manager, Biologics

 Watch Now

The Case for Intelligent Design (and Infrastructure) in Life Science Biologics R&D
Presented by IDC Health Insights’ Alan Louie and BIOVIA’s Tim Moran

With many recent blockbuster patents expiring, the pharmaceutical industry finds itself in the middle of a transformation. Leading life science organizations are updating their business strategies to include the pursuit of a new market opportunity – the discovery and development of biologic therapeutics. But despite the upside that accompanies this market shift, biologics R&D can be challenging due to process inefficiencies such as:

  • A lack of standardization in how experiment data is managed
  • Ineffective data mining capabilities that result in repeating experiments
  • Managing globally distributed teams that make collaboration difficult

Existing solutions can be pieced together to help get biologics to market, but they are not practical. In this webinar, IDC Health Insights’ Alan Louie and BIOVIA’s Tim Moran will examine challenges faced by life science R&D teams, keys to evolving for long-term sustainability and emerging holistic capabilities in biologics discovery and development.

 Watch Now


Browse By: